You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 19, 2024

GALLIUM DOTATATE GA-68 - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for gallium dotatate ga-68 and what is the scope of patent protection?

Gallium dotatate ga-68 is the generic ingredient in one branded drug marketed by Aaa Usa Inc and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Gallium dotatate ga-68 has thirty-two patent family members in nineteen countries.

One supplier is listed for this compound.

Summary for GALLIUM DOTATATE GA-68
International Patents:32
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 16
DailyMed Link:GALLIUM DOTATATE GA-68 at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for GALLIUM DOTATATE GA-68
Generic Entry Date for GALLIUM DOTATATE GA-68*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for GALLIUM DOTATATE GA-68

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Phase 2
First Affiliated Hospital of Fujian Medical UniversityEarly Phase 1
Peking Union Medical College HospitalEarly Phase 1

See all GALLIUM DOTATATE GA-68 clinical trials

US Patents and Regulatory Information for GALLIUM DOTATATE GA-68

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aaa Usa Inc NETSPOT gallium dotatate ga-68 POWDER;INTRAVENOUS 208547-001 Jun 1, 2016 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for GALLIUM DOTATATE GA-68

Country Patent Number Title Estimated Expiration
New Zealand 708281 Process for the preparation of complexes of 68ga ⤷  Try a Trial
Portugal 2742017 ⤷  Try a Trial
European Patent Office 2742017 PROCÉDÉ POUR LA PRÉPARATION DE COMPLEXES DE 68GA (PROCESS FOR THE PREPARATION OF COMPLEXES OF 68GA) ⤷  Try a Trial
Israel 230904 תהליך להכנת קומפלקסים של גאליום -68 (Process for the preparation of complexes of 68ga) ⤷  Try a Trial
Canada 2844145 PROCEDE POUR LA PREPARATION DE COMPLEXES DE 68GA (PROCESS FOR THE PREPARATION OF COMPLEXES OF 68GA) ⤷  Try a Trial
China 103889930 Process for the preparation of complexes of 68ga. ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.